96372 — “Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.” It is the generic administration code for a single SC or IM push of a non-vaccine, non-chemotherapy substance — almost certainly the highest-volume single administration CPT code billed, because it captures every office-administered injection that isn't a vaccine and isn't cancer treatment: denosumab (Prolia/Xgeva), inclisiran (Leqvio), vitamin B-12, corticosteroid depots, testosterone, and dozens of specialty biologics dosed by injection rather than infusion. 96372 is not the code for an IV infusion (96365), a chemotherapy or hormonal-chemotherapy SC/IM injection (96401/96402), a vaccine or toxoid (90471 family), or a drug the patient injected themselves (no administration code at all).
96372 lives in the AMA CPT manual's Therapeutic, Prophylactic, and Diagnostic Injections and Infusions subsection (96360-96379), the same family as hydration (96360/96361), therapeutic IV infusion (96365/96366), and IV push (96374/96375/96376). Route is what separates the family internally — 96372 is the subcutaneous/intramuscular member. CMS applies the CPT definition and administers the incident-to billing framework that governs it under Internet-Only Manual Publication 100-04 (Medicare Claims Processing Manual), Chapter 12, and the underlying supervision regulation at 42 CFR 410.26.
Because 96372's descriptor is a catch-all — “specify substance or drug” — the practical coding challenge isn't understanding what it covers so much as recognizing the four scenarios where it's the wrong code, or no code at all: the route was actually IV (wrong route — use 96365 or 96374), the substance was a vaccine or toxoid (wrong substance-type — use the immunization administration family), the substance was an antineoplastic agent (wrong classification — use 96401/96402), or the drug was self-administered by the patient rather than given by a clinician (no billable administration event exists at all).
96372 reports the administration work only. The injected drug itself is billed on its own HCPCS J-code (or Q-code) line, with JW/JZ waste modifiers applied where the drug is supplied in a single-dose container, and NDC as a secondary identifier increasingly required alongside the HCPCS code.
| Setting | CY2026 national Medicare payment |
|---|---|
| Non-facility (office) | $15.36 |
| Facility (HOPD / ASC) | $15.36 |
96372 pays under the Medicare Physician Fee Schedule (MPFS), not the ASP drug-payment system — this is the reimbursement for the injection service itself, separate from the J-code line for the injected drug (e.g., the J0897 line for a Prolia administration). Total RVUs are 0.46 (work 0.17 + practice expense 0.28 + malpractice 0.01) against an XXX global period, with identical facility and non-facility practice-expense RVUs — so the national payment does not change by site of service.
CY2026 national rates; MAC-adjusted locally. These are unadjusted national base rates (work + practice-expense + malpractice RVUs × conversion factor $33.4009) before your Medicare Administrative Contractor's geographic practice cost index (GPCI). Actual payment in your locality will differ. Full rate table and sources: /data/mpfs-admin-rates.json.
In practice, 96372 shows up most often on quarterly or biannual injectable-biologic maintenance visits — Prolia every six months for osteoporosis, Leqvio at day 1, month 3, then every six months for LDL-C management, monthly testosterone or vitamin B-12 injections in primary care. The single most common judgment call is the antineoplastic classification test in step 3: a drug's oncology indication does not automatically make it antineoplastic for CPT purposes — denosumab is the textbook exception every biller eventually runs into.
The two largest denial patterns are opposite failure modes: billing 96372 for a vaccine (should route to the 90471 family), and billing 96372 — plus the drug line — for a substance the patient actually self-administers at home. The second pattern is more consequential, because when a drug is on the payer's self-administered drug list, the whole claim denies, not just the administration line; there was never a billable clinician-performed service to code in the first place.
96372 is a stable AMA CPT construct that every major payer honors identically at the code-definition level. Divergence shows up in two places: each Medicare Administrative Contractor sets its own self-administered drug (SAD) list, so the same SC/IM drug can be Part B-payable (96372 billable) in one MAC jurisdiction and Part D-only (no 96372) in another; and payers differ on whether a second same-encounter injection expects modifier 59, a more specific X{EPSU} modifier, or a straightforward second unit.
| Payer | Aligned with AMA definition? | Notes |
|---|---|---|
| Medicare (Part B) | Yes | Source-of-truth payer. Each of the 12 MAC jurisdictions publishes its own SAD list, so 96372/drug billability for a given SC/IM product varies by state. CY2026 MPFS Final Rule (CMS-1832-F) made virtual direct supervision permanent, effective January 1, 2026. |
| UnitedHealthcare | Yes | Aligns with CMS at adjudication. OptumRx specialty-pharmacy fulfillment for injectable biologics (e.g., Leqvio, Prolia) doesn't change the administration coding — the practice still bills 96372 for the injection regardless of how the drug was sourced. |
| Aetna (CVS Health) | Yes | Aligns with CMS. Aetna's own self-administered-drug exclusion policy generally mirrors CMS's list logic for commercial plans, though the specific excluded drugs can differ from any individual MAC's list. |
| Cigna / Express Scripts | Yes | Aligns with CMS. Accredo specialty-pharmacy white-bag fulfillment is common for several 96372-billed biologics; the administering practice still bills 96372 for the injection. |
| Humana | Yes | MA-heavy book follows CMS SAD-list logic by default. CenterWell Specialty fulfills a number of 96372-family injectables for Humana MA members. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| 96372 billed for vaccine administration | A vaccine or toxoid injection was coded as 96372 instead of the immunization administration family. AMA CPT explicitly excludes vaccines from 96372. | Resubmit with the appropriate immunization administration code (90460-90474 or 90471-90474). Appeal language: “Per AMA CPT, 96372 excludes administration of a vaccine or toxoid; the corrected claim reports the immunization administration code appropriate to counseling and patient age.” |
| 96372 used for an antineoplastic SC/IM drug | A cancer-treatment drug (cytotoxic or hormonal antineoplastic) was downcoded to 96372, which carries a lower administration RVU than 96401/96402. | Resubmit with 96401 (non-hormonal) or 96402 (hormonal antineoplastic), as appropriate. Appeal language: “The drug administered is an antineoplastic agent per AMA CPT classification; the corrected administration code reflects the chemotherapy SC/IM family, not the generic therapeutic-injection code.” |
| 96372 + drug billed for a self-administered/SAD-list product | The claim billed 96372 and the drug's J-code for a substance the payer's self-administered drug list excludes from Part B (or the equivalent commercial exclusion), because the drug is usually patient-self-injected. | Confirm whether the specific encounter genuinely involved clinician administration (patient unable to self-inject) and document accordingly, or withdraw the claim if the drug was in fact self-administered. Appeal language, where clinician administration is documented: “The patient was unable to self-administer this encounter; administration was performed by clinical staff as documented in the medical record, supporting billing of 96372 and the drug line notwithstanding the drug's usual self-administered status.” |
| Second 96372 line denied as duplicate | A second, genuinely distinct injection at the same encounter was billed as a second 96372 line without a distinct-procedural-service modifier, and NCCI or the payer's edit logic rejected it as a duplicate of the first line. | Resubmit the second line with modifier 59 (or the payer's preferred X{EPSU} modifier, e.g., XS). Appeal language: “Two genuinely distinct substances were injected at this encounter, as documented by separate drug names, sites, and indications in the medical record. Modifier 59 (or XS) was added to the second 96372 line to indicate the distinct procedural service.” |
| 96372 denied for missing supervision documentation | An incident-to 96372 line was billed by clinical staff without documentation establishing the supervising physician/NPP and their availability during the service, per 42 CFR 410.26. | Ensure the medical record identifies the supervising clinician and their mode of presence (in-suite or, since January 1, 2026, qualifying real-time audio-video presence per the CY2026 MPFS Final Rule) for every incident-to administration. Appeal language: “The service was furnished incident-to [supervising clinician], who was directly supervising per 42 CFR 410.26 as documented in the encounter note.” |
96372 — “Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.” It is the generic administration code for a single SC or IM injection of a non-vaccine, non-chemotherapy substance — depot hormones, biologics like denosumab (Prolia/Xgeva) and inclisiran (Leqvio), vitamin B-12, corticosteroid depots, and dozens of other office-administered injectables. It reports the administration work only; the drug itself is billed separately on its own HCPCS J-code or Q-code line.
Route. 96372 is for a subcutaneous or intramuscular injection — a single push of drug from a syringe, typically finished in under a minute. 96365 is for an intravenous infusion — the drug is delivered through an IV line over time (initial hour, then 96366 for each additional hour). The same drug can theoretically be formulated for either route, but the administration code follows how it was actually given at that encounter.
When the injected substance is an antineoplastic (cancer-treatment) agent. 96401 covers non-hormonal antineoplastic SC/IM injections; 96402 covers hormonal antineoplastic SC/IM injections (leuprolide, fulvestrant, degarelix for a cancer indication). Denosumab (Prolia/Xgeva) is a notable exception that stays on 96372 even in an oncology chart — it's a RANKL-inhibitor supportive-care agent, not a cytotoxic or antineoplastic drug under the AMA CPT chemotherapy-administration definition.
No. AMA CPT explicitly directs that 96372 is not reported for administration of a vaccine or toxoid — that belongs to the immunization administration family (90460-90474 for the counseling-based pediatric model, 90471-90474 for the non-counseling model). A same-day visit that includes both a vaccine and a non-vaccine therapeutic injection can bill both as two distinct services.
No. 96372 requires an actual clinician-performed (or clinical-staff, incident-to a supervising physician/NPP) administration event. If a patient self-injects a subcutaneous drug at home — common for autoinjector or prefilled-pen products like Ajovy — there is no billable administration service at all. Many self-injected SC/IM drugs also appear on a Medicare Administrative Contractor's self-administered drug (SAD) list, which excludes the drug itself from Part B precisely because it's usually self-administered.
When clinical staff performs the injection, it is billed incident-to under 42 CFR 410.26, which requires direct supervision — the supervising physician or qualifying non-physician practitioner must be immediately available to furnish assistance during the service. Effective January 1, 2026, the CY2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) made permanent a policy allowing direct supervision to be satisfied through real-time, interactive audio-video technology rather than requiring physical presence in the office suite.
Generally yes, if two genuinely distinct substances are injected at the same visit. Convention is one 96372 line for the first injection and a second 96372 line appended with modifier 59 (or the more specific X{EPSU} modifier, most often XS) for the additional injection, since 96372 is not an add-on code and NCCI will otherwise treat a repeated line as a duplicate. Confirm the specific payer's edit policy before submitting.
All sources are publicly available federal publications or paraphrased from AMA / CMS / legal-industry educational materials. AMA CPT code descriptors are reproduced under fair-use reference; full descriptors require an AMA CPT license. The methodology by which we resolve source disagreements is described in the Methodology.